Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT
Purpose To depict treatment response to chemoradiotherapy by comparing tumor growth rate between treated and untreated patients and to compare depicted response with objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guideline. Methods and Materials This He...
Gespeichert in:
| Veröffentlicht in: | International journal of radiation oncology, biology, physics biology, physics, 2011-10, Vol.81 (2), p.452-459 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 459 |
|---|---|
| container_issue | 2 |
| container_start_page | 452 |
| container_title | International journal of radiation oncology, biology, physics |
| container_volume | 81 |
| creator | Rezai, Pedram, M.D Yaghmai, Vahid, M.D Tochetto, Sandra M., M.D Galizia, Mauricio S., M.D Miller, Frank H., M.D Mulcahy, Mary F., M.D Small, William, M.D., F.A.C.R.O |
| description | Purpose To depict treatment response to chemoradiotherapy by comparing tumor growth rate between treated and untreated patients and to compare depicted response with objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guideline. Methods and Materials This Health Insurance Portability and Accountability Act–compliant, retrospective study was approved by the institutional review board. Volume doubling time (DT) of histologically confirmed locally advanced pancreatic adenocarcinoma was calculated in 16 patients treated with chemoradiotherapy and 10 untreated patients by incorporating interscan interval (Δt) and tumor volume at baseline (V0) and follow-up (V1) obtained by semiautomated segmentation into the following equation: DT = Δt · log 2/log (V1/V0). Reciprocal of doubling time (RDT), which is the linear representation of tumor growth rate, was calculated by use of the following equation: RDT = 365/DT. The lowest RDT value of 2.42 in untreated patients was considered as the cutoff value for depiction of treatment response. Depicted response rate was defined as the proportion of patients with an RDT value of less than 2.42. Depicted response was compared with objective response according to the RECIST 1.1 guideline. The significance level was set at p < 0.05. Results There was a significant difference in mean RDT between treated (range, −7.12 to 3.27; mean, −1.27; median, −1.30) and untreated (range, 2.42 to 10.74; mean, 5.33; median, 4.26) patients ( p < 0.05). Reciprocal of doubling time was less than 2.42 in 14 treated patients, which corresponded to a depicted response rate of 87.50% as opposed to the objective response rate of 18.75% according to the RECIST 1.1 guideline ( p < 0.05) and carbohydrate antigen 19-9 response rate of 62.50% ( p > 0.05). Carbohydrate antigen 19-9 response was concordant with RDT and RECIST response in 12 patients (75.00%) (κ, 0.38) and 9 patients (56.25%) (κ, 0.24), respectively. Conclusions There was a significant difference between depicted response according to RDT and objective response according to RECIST. Reciprocal of doubling time might serve as a valuable biomarker for evaluation of treatment response when depiction of small changes in tumor size is concerned. |
| doi_str_mv | 10.1016/j.ijrobp.2010.05.060 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_osti_</sourceid><recordid>TN_cdi_osti_scitechconnect_21587733</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0360301610008084</els_id><sourcerecordid>885906337</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-1f72a49aa9f8a2194c6956896968ed2af2707e8d5d1ea7111e62ff881f0e8a103</originalsourceid><addsrcrecordid>eNqFks-O0zAQxiMEYsvCGyBkCSEu22LHSexcVloKFKQi0FIkbtbUmVCHxA62u6j7Arw2jlpA4sLJ1ug33_z5JsseM7pglFUvuoXpvNuOi5ymEC0XtKJ3shmTop7zsvxyN5tRXtE5T_BZ9iCEjlLKmCjuZ2c5KwVldT3Lfi53YL8iMZbEHZKVdz_ijlxDROJasnYaenOLDfkIVnuEaDS5atCmuNfGugGmzGsMo7MBSXRkhYM2EbbG4gV5iTegze1-gO0FAdsk4cYkEWfJZocexgNJ3_evlpuH2b0W-oCPTu959vnN683y7Xz9YfVuebWe60IUcc5akUNRA9SthJzVha7qspJ1VVcSmxzaXFCBsikbhiAYY1jlbSslaylKYJSfZ0-Pui5Eo0JqFfVOO2tRR5XWIoXgPFHPj9To3fc9hqgGEzT2PVh0-6CkLGtacS4SWRxJ7V0IHls1ejOAPyhG1eST6tTRJzX5pGipkk8p7cmpwH47YPMn6bcxCXh2AiAkD1qf9m_CX64oGed5mbjLI4dpaTcG_TQTWo2N8dNIjTP_6-RfAd0ba1LNb3jA0Lm9t8kQxVTIFVWfppuaToqla5JUFvwXq4vGxQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>885906337</pqid></control><display><type>article</type><title>Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Rezai, Pedram, M.D ; Yaghmai, Vahid, M.D ; Tochetto, Sandra M., M.D ; Galizia, Mauricio S., M.D ; Miller, Frank H., M.D ; Mulcahy, Mary F., M.D ; Small, William, M.D., F.A.C.R.O</creator><creatorcontrib>Rezai, Pedram, M.D ; Yaghmai, Vahid, M.D ; Tochetto, Sandra M., M.D ; Galizia, Mauricio S., M.D ; Miller, Frank H., M.D ; Mulcahy, Mary F., M.D ; Small, William, M.D., F.A.C.R.O</creatorcontrib><description>Purpose To depict treatment response to chemoradiotherapy by comparing tumor growth rate between treated and untreated patients and to compare depicted response with objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guideline. Methods and Materials This Health Insurance Portability and Accountability Act–compliant, retrospective study was approved by the institutional review board. Volume doubling time (DT) of histologically confirmed locally advanced pancreatic adenocarcinoma was calculated in 16 patients treated with chemoradiotherapy and 10 untreated patients by incorporating interscan interval (Δt) and tumor volume at baseline (V0) and follow-up (V1) obtained by semiautomated segmentation into the following equation: DT = Δt · log 2/log (V1/V0). Reciprocal of doubling time (RDT), which is the linear representation of tumor growth rate, was calculated by use of the following equation: RDT = 365/DT. The lowest RDT value of 2.42 in untreated patients was considered as the cutoff value for depiction of treatment response. Depicted response rate was defined as the proportion of patients with an RDT value of less than 2.42. Depicted response was compared with objective response according to the RECIST 1.1 guideline. The significance level was set at p < 0.05. Results There was a significant difference in mean RDT between treated (range, −7.12 to 3.27; mean, −1.27; median, −1.30) and untreated (range, 2.42 to 10.74; mean, 5.33; median, 4.26) patients ( p < 0.05). Reciprocal of doubling time was less than 2.42 in 14 treated patients, which corresponded to a depicted response rate of 87.50% as opposed to the objective response rate of 18.75% according to the RECIST 1.1 guideline ( p < 0.05) and carbohydrate antigen 19-9 response rate of 62.50% ( p > 0.05). Carbohydrate antigen 19-9 response was concordant with RDT and RECIST response in 12 patients (75.00%) (κ, 0.38) and 9 patients (56.25%) (κ, 0.24), respectively. Conclusions There was a significant difference between depicted response according to RDT and objective response according to RECIST. Reciprocal of doubling time might serve as a valuable biomarker for evaluation of treatment response when depiction of small changes in tumor size is concerned.</description><identifier>ISSN: 0360-3016</identifier><identifier>EISSN: 1879-355X</identifier><identifier>DOI: 10.1016/j.ijrobp.2010.05.060</identifier><identifier>PMID: 21570199</identifier><identifier>CODEN: IOBPD3</identifier><language>eng</language><publisher>New York, NY: Elsevier Inc</publisher><subject>Aged ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; ANTIGENS ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Bevacizumab ; Biological and medical sciences ; BIOLOGICAL MARKERS ; BODY ; CA-19-9 Antigen - blood ; Carcinoma, Pancreatic Ductal - drug therapy ; Carcinoma, Pancreatic Ductal - pathology ; Carcinoma, Pancreatic Ductal - radiotherapy ; CARCINOMAS ; Chemoradiotherapy ; Chemotherapy ; COMBINED THERAPY ; Combined treatments (chemotherapy of immunotherapy associated with an other treatment) ; Deoxycytidine - administration & dosage ; Deoxycytidine - analogs & derivatives ; DIGESTIVE SYSTEM ; DISEASES ; Doubling time ; Drug Administration Schedule ; ENDOCRINE GLANDS ; EQUATIONS ; Female ; Gastroenterology. Liver. Pancreas. Abdomen ; GLANDS ; Growth rate ; Guideline Adherence ; Hematology, Oncology and Palliative Medicine ; Humans ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Male ; Medical sciences ; MEDICINE ; Middle Aged ; NEOPLASMS ; NUCLEAR MEDICINE ; ORGANS ; PANCREAS ; Pancreatic adenocarcinoma ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - pathology ; Pancreatic Neoplasms - radiotherapy ; Pharmacology. Drug treatments ; RADIOLOGY ; RADIOLOGY AND NUCLEAR MEDICINE ; RADIOTHERAPY ; Retrospective Studies ; THERAPY ; Time Factors ; Treatment Outcome ; Treatment response ; Tumor Burden - drug effects ; Tumor Burden - physiology ; Tumor Burden - radiation effects ; Tumors</subject><ispartof>International journal of radiation oncology, biology, physics, 2011-10, Vol.81 (2), p.452-459</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-1f72a49aa9f8a2194c6956896968ed2af2707e8d5d1ea7111e62ff881f0e8a103</citedby><cites>FETCH-LOGICAL-c474t-1f72a49aa9f8a2194c6956896968ed2af2707e8d5d1ea7111e62ff881f0e8a103</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ijrobp.2010.05.060$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,777,781,882,3538,27906,27907,45977</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24513325$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21570199$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.osti.gov/biblio/21587733$$D View this record in Osti.gov$$Hfree_for_read</backlink></links><search><creatorcontrib>Rezai, Pedram, M.D</creatorcontrib><creatorcontrib>Yaghmai, Vahid, M.D</creatorcontrib><creatorcontrib>Tochetto, Sandra M., M.D</creatorcontrib><creatorcontrib>Galizia, Mauricio S., M.D</creatorcontrib><creatorcontrib>Miller, Frank H., M.D</creatorcontrib><creatorcontrib>Mulcahy, Mary F., M.D</creatorcontrib><creatorcontrib>Small, William, M.D., F.A.C.R.O</creatorcontrib><title>Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT</title><title>International journal of radiation oncology, biology, physics</title><addtitle>Int J Radiat Oncol Biol Phys</addtitle><description>Purpose To depict treatment response to chemoradiotherapy by comparing tumor growth rate between treated and untreated patients and to compare depicted response with objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guideline. Methods and Materials This Health Insurance Portability and Accountability Act–compliant, retrospective study was approved by the institutional review board. Volume doubling time (DT) of histologically confirmed locally advanced pancreatic adenocarcinoma was calculated in 16 patients treated with chemoradiotherapy and 10 untreated patients by incorporating interscan interval (Δt) and tumor volume at baseline (V0) and follow-up (V1) obtained by semiautomated segmentation into the following equation: DT = Δt · log 2/log (V1/V0). Reciprocal of doubling time (RDT), which is the linear representation of tumor growth rate, was calculated by use of the following equation: RDT = 365/DT. The lowest RDT value of 2.42 in untreated patients was considered as the cutoff value for depiction of treatment response. Depicted response rate was defined as the proportion of patients with an RDT value of less than 2.42. Depicted response was compared with objective response according to the RECIST 1.1 guideline. The significance level was set at p < 0.05. Results There was a significant difference in mean RDT between treated (range, −7.12 to 3.27; mean, −1.27; median, −1.30) and untreated (range, 2.42 to 10.74; mean, 5.33; median, 4.26) patients ( p < 0.05). Reciprocal of doubling time was less than 2.42 in 14 treated patients, which corresponded to a depicted response rate of 87.50% as opposed to the objective response rate of 18.75% according to the RECIST 1.1 guideline ( p < 0.05) and carbohydrate antigen 19-9 response rate of 62.50% ( p > 0.05). Carbohydrate antigen 19-9 response was concordant with RDT and RECIST response in 12 patients (75.00%) (κ, 0.38) and 9 patients (56.25%) (κ, 0.24), respectively. Conclusions There was a significant difference between depicted response according to RDT and objective response according to RECIST. Reciprocal of doubling time might serve as a valuable biomarker for evaluation of treatment response when depiction of small changes in tumor size is concerned.</description><subject>Aged</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>ANTIGENS</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Bevacizumab</subject><subject>Biological and medical sciences</subject><subject>BIOLOGICAL MARKERS</subject><subject>BODY</subject><subject>CA-19-9 Antigen - blood</subject><subject>Carcinoma, Pancreatic Ductal - drug therapy</subject><subject>Carcinoma, Pancreatic Ductal - pathology</subject><subject>Carcinoma, Pancreatic Ductal - radiotherapy</subject><subject>CARCINOMAS</subject><subject>Chemoradiotherapy</subject><subject>Chemotherapy</subject><subject>COMBINED THERAPY</subject><subject>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</subject><subject>Deoxycytidine - administration & dosage</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>DIGESTIVE SYSTEM</subject><subject>DISEASES</subject><subject>Doubling time</subject><subject>Drug Administration Schedule</subject><subject>ENDOCRINE GLANDS</subject><subject>EQUATIONS</subject><subject>Female</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>GLANDS</subject><subject>Growth rate</subject><subject>Guideline Adherence</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>Humans</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Male</subject><subject>Medical sciences</subject><subject>MEDICINE</subject><subject>Middle Aged</subject><subject>NEOPLASMS</subject><subject>NUCLEAR MEDICINE</subject><subject>ORGANS</subject><subject>PANCREAS</subject><subject>Pancreatic adenocarcinoma</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Pancreatic Neoplasms - radiotherapy</subject><subject>Pharmacology. Drug treatments</subject><subject>RADIOLOGY</subject><subject>RADIOLOGY AND NUCLEAR MEDICINE</subject><subject>RADIOTHERAPY</subject><subject>Retrospective Studies</subject><subject>THERAPY</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><subject>Treatment response</subject><subject>Tumor Burden - drug effects</subject><subject>Tumor Burden - physiology</subject><subject>Tumor Burden - radiation effects</subject><subject>Tumors</subject><issn>0360-3016</issn><issn>1879-355X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks-O0zAQxiMEYsvCGyBkCSEu22LHSexcVloKFKQi0FIkbtbUmVCHxA62u6j7Arw2jlpA4sLJ1ug33_z5JsseM7pglFUvuoXpvNuOi5ymEC0XtKJ3shmTop7zsvxyN5tRXtE5T_BZ9iCEjlLKmCjuZ2c5KwVldT3Lfi53YL8iMZbEHZKVdz_ijlxDROJasnYaenOLDfkIVnuEaDS5atCmuNfGugGmzGsMo7MBSXRkhYM2EbbG4gV5iTegze1-gO0FAdsk4cYkEWfJZocexgNJ3_evlpuH2b0W-oCPTu959vnN683y7Xz9YfVuebWe60IUcc5akUNRA9SthJzVha7qspJ1VVcSmxzaXFCBsikbhiAYY1jlbSslaylKYJSfZ0-Pui5Eo0JqFfVOO2tRR5XWIoXgPFHPj9To3fc9hqgGEzT2PVh0-6CkLGtacS4SWRxJ7V0IHls1ejOAPyhG1eST6tTRJzX5pGipkk8p7cmpwH47YPMn6bcxCXh2AiAkD1qf9m_CX64oGed5mbjLI4dpaTcG_TQTWo2N8dNIjTP_6-RfAd0ba1LNb3jA0Lm9t8kQxVTIFVWfppuaToqla5JUFvwXq4vGxQ</recordid><startdate>20111001</startdate><enddate>20111001</enddate><creator>Rezai, Pedram, M.D</creator><creator>Yaghmai, Vahid, M.D</creator><creator>Tochetto, Sandra M., M.D</creator><creator>Galizia, Mauricio S., M.D</creator><creator>Miller, Frank H., M.D</creator><creator>Mulcahy, Mary F., M.D</creator><creator>Small, William, M.D., F.A.C.R.O</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>OTOTI</scope></search><sort><creationdate>20111001</creationdate><title>Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT</title><author>Rezai, Pedram, M.D ; Yaghmai, Vahid, M.D ; Tochetto, Sandra M., M.D ; Galizia, Mauricio S., M.D ; Miller, Frank H., M.D ; Mulcahy, Mary F., M.D ; Small, William, M.D., F.A.C.R.O</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-1f72a49aa9f8a2194c6956896968ed2af2707e8d5d1ea7111e62ff881f0e8a103</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Aged</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>ANTIGENS</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Bevacizumab</topic><topic>Biological and medical sciences</topic><topic>BIOLOGICAL MARKERS</topic><topic>BODY</topic><topic>CA-19-9 Antigen - blood</topic><topic>Carcinoma, Pancreatic Ductal - drug therapy</topic><topic>Carcinoma, Pancreatic Ductal - pathology</topic><topic>Carcinoma, Pancreatic Ductal - radiotherapy</topic><topic>CARCINOMAS</topic><topic>Chemoradiotherapy</topic><topic>Chemotherapy</topic><topic>COMBINED THERAPY</topic><topic>Combined treatments (chemotherapy of immunotherapy associated with an other treatment)</topic><topic>Deoxycytidine - administration & dosage</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>DIGESTIVE SYSTEM</topic><topic>DISEASES</topic><topic>Doubling time</topic><topic>Drug Administration Schedule</topic><topic>ENDOCRINE GLANDS</topic><topic>EQUATIONS</topic><topic>Female</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>GLANDS</topic><topic>Growth rate</topic><topic>Guideline Adherence</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>Humans</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Male</topic><topic>Medical sciences</topic><topic>MEDICINE</topic><topic>Middle Aged</topic><topic>NEOPLASMS</topic><topic>NUCLEAR MEDICINE</topic><topic>ORGANS</topic><topic>PANCREAS</topic><topic>Pancreatic adenocarcinoma</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Pancreatic Neoplasms - radiotherapy</topic><topic>Pharmacology. Drug treatments</topic><topic>RADIOLOGY</topic><topic>RADIOLOGY AND NUCLEAR MEDICINE</topic><topic>RADIOTHERAPY</topic><topic>Retrospective Studies</topic><topic>THERAPY</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><topic>Treatment response</topic><topic>Tumor Burden - drug effects</topic><topic>Tumor Burden - physiology</topic><topic>Tumor Burden - radiation effects</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rezai, Pedram, M.D</creatorcontrib><creatorcontrib>Yaghmai, Vahid, M.D</creatorcontrib><creatorcontrib>Tochetto, Sandra M., M.D</creatorcontrib><creatorcontrib>Galizia, Mauricio S., M.D</creatorcontrib><creatorcontrib>Miller, Frank H., M.D</creatorcontrib><creatorcontrib>Mulcahy, Mary F., M.D</creatorcontrib><creatorcontrib>Small, William, M.D., F.A.C.R.O</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>OSTI.GOV</collection><jtitle>International journal of radiation oncology, biology, physics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rezai, Pedram, M.D</au><au>Yaghmai, Vahid, M.D</au><au>Tochetto, Sandra M., M.D</au><au>Galizia, Mauricio S., M.D</au><au>Miller, Frank H., M.D</au><au>Mulcahy, Mary F., M.D</au><au>Small, William, M.D., F.A.C.R.O</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT</atitle><jtitle>International journal of radiation oncology, biology, physics</jtitle><addtitle>Int J Radiat Oncol Biol Phys</addtitle><date>2011-10-01</date><risdate>2011</risdate><volume>81</volume><issue>2</issue><spage>452</spage><epage>459</epage><pages>452-459</pages><issn>0360-3016</issn><eissn>1879-355X</eissn><coden>IOBPD3</coden><abstract>Purpose To depict treatment response to chemoradiotherapy by comparing tumor growth rate between treated and untreated patients and to compare depicted response with objective response according to the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 guideline. Methods and Materials This Health Insurance Portability and Accountability Act–compliant, retrospective study was approved by the institutional review board. Volume doubling time (DT) of histologically confirmed locally advanced pancreatic adenocarcinoma was calculated in 16 patients treated with chemoradiotherapy and 10 untreated patients by incorporating interscan interval (Δt) and tumor volume at baseline (V0) and follow-up (V1) obtained by semiautomated segmentation into the following equation: DT = Δt · log 2/log (V1/V0). Reciprocal of doubling time (RDT), which is the linear representation of tumor growth rate, was calculated by use of the following equation: RDT = 365/DT. The lowest RDT value of 2.42 in untreated patients was considered as the cutoff value for depiction of treatment response. Depicted response rate was defined as the proportion of patients with an RDT value of less than 2.42. Depicted response was compared with objective response according to the RECIST 1.1 guideline. The significance level was set at p < 0.05. Results There was a significant difference in mean RDT between treated (range, −7.12 to 3.27; mean, −1.27; median, −1.30) and untreated (range, 2.42 to 10.74; mean, 5.33; median, 4.26) patients ( p < 0.05). Reciprocal of doubling time was less than 2.42 in 14 treated patients, which corresponded to a depicted response rate of 87.50% as opposed to the objective response rate of 18.75% according to the RECIST 1.1 guideline ( p < 0.05) and carbohydrate antigen 19-9 response rate of 62.50% ( p > 0.05). Carbohydrate antigen 19-9 response was concordant with RDT and RECIST response in 12 patients (75.00%) (κ, 0.38) and 9 patients (56.25%) (κ, 0.24), respectively. Conclusions There was a significant difference between depicted response according to RDT and objective response according to RECIST. Reciprocal of doubling time might serve as a valuable biomarker for evaluation of treatment response when depiction of small changes in tumor size is concerned.</abstract><cop>New York, NY</cop><pub>Elsevier Inc</pub><pmid>21570199</pmid><doi>10.1016/j.ijrobp.2010.05.060</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0360-3016 |
| ispartof | International journal of radiation oncology, biology, physics, 2011-10, Vol.81 (2), p.452-459 |
| issn | 0360-3016 1879-355X |
| language | eng |
| recordid | cdi_osti_scitechconnect_21587733 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized ANTIGENS Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Biological and medical sciences BIOLOGICAL MARKERS BODY CA-19-9 Antigen - blood Carcinoma, Pancreatic Ductal - drug therapy Carcinoma, Pancreatic Ductal - pathology Carcinoma, Pancreatic Ductal - radiotherapy CARCINOMAS Chemoradiotherapy Chemotherapy COMBINED THERAPY Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Deoxycytidine - administration & dosage Deoxycytidine - analogs & derivatives DIGESTIVE SYSTEM DISEASES Doubling time Drug Administration Schedule ENDOCRINE GLANDS EQUATIONS Female Gastroenterology. Liver. Pancreas. Abdomen GLANDS Growth rate Guideline Adherence Hematology, Oncology and Palliative Medicine Humans Liver. Biliary tract. Portal circulation. Exocrine pancreas Male Medical sciences MEDICINE Middle Aged NEOPLASMS NUCLEAR MEDICINE ORGANS PANCREAS Pancreatic adenocarcinoma Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - pathology Pancreatic Neoplasms - radiotherapy Pharmacology. Drug treatments RADIOLOGY RADIOLOGY AND NUCLEAR MEDICINE RADIOTHERAPY Retrospective Studies THERAPY Time Factors Treatment Outcome Treatment response Tumor Burden - drug effects Tumor Burden - physiology Tumor Burden - radiation effects Tumors |
| title | Change in the Growth Rate of Localized Pancreatic Adenocarcinoma in Response to Gemcitabine, Bevacizumab, and Radiation Therapy on MDCT |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T11%3A28%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_osti_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Change%20in%20the%20Growth%20Rate%20of%20Localized%20Pancreatic%20Adenocarcinoma%20in%20Response%20to%20Gemcitabine,%20Bevacizumab,%20and%20Radiation%20Therapy%20on%20MDCT&rft.jtitle=International%20journal%20of%20radiation%20oncology,%20biology,%20physics&rft.au=Rezai,%20Pedram,%20M.D&rft.date=2011-10-01&rft.volume=81&rft.issue=2&rft.spage=452&rft.epage=459&rft.pages=452-459&rft.issn=0360-3016&rft.eissn=1879-355X&rft.coden=IOBPD3&rft_id=info:doi/10.1016/j.ijrobp.2010.05.060&rft_dat=%3Cproquest_osti_%3E885906337%3C/proquest_osti_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=885906337&rft_id=info:pmid/21570199&rft_els_id=S0360301610008084&rfr_iscdi=true |